Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 30;38(4):418-426.
doi: 10.2478/jomb-2019-0002. eCollection 2019 Oct.

Correlation of Fgf23 and Balp with Bone Mineral Density in Hemodialysis Patients

Mouna Bouksila  1 , Mehdi Mrad  2 , Wajih Kaabachi  3 , Eya Kalai  1 , Wided Smaoui  4 , Sonia Rekik  5 , Asma Krir  2 , Nesrine Issaoui  2 , Kamel Hamzaoui  3 , Hela Sahli  1 , Elhem Cheour El Kateb  1 , Mohammed Karim Zouaghi  4 , Afef Bahlous  2
Affiliations

Correlation of Fgf23 and Balp with Bone Mineral Density in Hemodialysis Patients

Mouna Bouksila et al. J Med Biochem. .

Abstract
in English, Serbian

Background: Chronic kidney disease (CKD) is associated with numerous complications such as bone mineral disorder. The aim of our study was to analyze the correlation of bone turnover markers with Bone Mineral Density (BMD) measurements in Tunisian end stage renal diseases (ESRD) patients.

Methods: This study included 100 ESRD Tunisian patients. Their estimated glomerular filtration rate (eGFR) was < 15 mL × min-1 × (1.73 m2)-1, which requires hemodialysis. Bone-specific alkaline phosphatase (BALP) serum concentration was determined with a chemiluminescence immunoassay. Fibroblast Growth Factor 23 (FGF23) serum was assessed by Enzyme-Linked Immunosorbent Assay method. The serum levels of 25-Hydroxyvitamin D (25(OH)D), intact parathyroid hormone (iPTH) and Beta cross-laps (CTX) was measured by Electrochemiluminescence Technology. DEXA (dual-energy x-ray absorptiometry) technique was used to evaluate BMD.

Results: We observed a statistically significant negative correlation between BALP levels and total body BMD (r = -0.268; P = 0.015) particularly in femoral neck (FN) (r = -0.219; P = 0.037). BALP concentrations were negatively associated with total BMD especially in FN for patients with BMI < 30, FGF23 concentrations were also negatively correlated with BMD in lumbar spine site (LS) (r = -0.209; P = 0.046). For osteopenic patients we found an inverse correlation between 25(OH)D concentrations and BMD in LS position (r = -0.336; P = 0.038). In men group, we have also found a negative correlation between iPTH and total BMD (r = -0.326; P = 0.015). However we found a positive correlation between calcium expression and BMD in LS site (r = 0.270; P = 0.031).

Conclusions: FGF23 and BALP can predict bone loss in ESRD through their strong correlation with BMD in LS and FN sites respectively.

Uvod: Hronično bubrežno oboljenje (CKD) je praćeno brojnim komplikacijama kao što je poremećaj minerala kostiju. Svha ovog izučavanja je bila da analizira korelaciju markera promena u kostima sa mineralnom gustinom kostiju (BMD) i stupnja renalnih oboljenja kod pacijenata u Tunisu.

Metode: Proučavanje je uključilo 100 ESRD tuniskih pacijenata. Njihova prosečna brzina glomerularne filtracije (eGFR) bila je < 15 mL × min-1 × (1,73 m2)-1 što je zahtevalo hemodijalizu. Koštana alkalna fosfataza (BLAP) određena je u serumu hemilumiiscentnom imuno metodom. Faktor rasta fibroblasta 23 (FGF23) u serumu određen je enzimskom imunosorbetnom metodom. Nivoi 25-hidroksivitamina D (25(OH)D), intaktnog paratiroidnog hormona (iPTH) i betakros-lapsa (CTX) izmereni su elektrohemiluminiscentnom DEXA tehnologijom (dual-energy x-ray apsorpciometrijom) kako bi se procenila BMD.

Rezultati: Nađena je značajno negativna statistička korelacija BALP nivoa i ukupnog telesnog BMD (r= -0,268: P = 0,015) u femoralnom delu vrata (FN) (r = -0,219; P = 0,037). BALP je bila u negativnoj korelaciji sa ukupnom BMD naročito kod FN pacijenata sa BMI < 30, FGF23 koncentracije su bile takođe u negativnoj korelaciji sa BMD u lumbalnom delu (LS) (r = -0,209, P = 0,046). Kod osteopeničnih pacijenata nađene je inverzna korelacija između 25(OH)D koncentracije i DMD u LS polažaju (r = -0,336; P = 0,038). U grupi muških osoba nađena je negativna korelacija između iPTH i ukupnog BMD (r = -0,326; P = 0,015). Međutim, nađena je pozitivna korelacija između ekspresije kalcijuma i BMD u LS (r = 0,270: P = 0,031).

Zaključak: FGF23 i BALP mogu da predvide gubitak kosti kod ESRD preko izrazite korelacije sa BMD u LS i FN položajima.

Keywords: 25-Hydroxyvitamin D; bone alkaline phosphatase; bone mineral density; bone mineral disorder; chronic kidney disease; fibroblast growth factor 23.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Conflict of interest statement: The authors stated that they have no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Correlation between BALP, FGF23 levels and BMD in hemodialysis patients A: Correlation between BALP levels and total BMD in hemodialysis patients; B: Correlation between BALP and BMD in FN in hemodialysis patients; C: Correlation between FGF23 levels and LS-BMD in hemodialysis patients; D: Correlation between FGF23 levels and LS-T scores in hemodialysis patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Belino C, Meng C, Pereira L, Carvalho C, Neto R. The role of bone biomarkers and new imaging techniques in the management of patients with CKD-MBD. Port J Nephrol Hypert. 2017;31:293–9.
    1. Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Am J Kidney Dis 2017; 70:737–51. - PubMed
    1. Stefanović A, Ristovski-Kornic D, Kotur-Stevuljević J, Spasojević-Kalimanovska V, Vekić J, Miljković M, Paripović D, Peco-Antic A, Jelić-Ivanović Z, Zeljković A. Alterations of HDL particles in children with end-stage renal disease. J Med Biochem. 2017;36:358–65. - PMC - PubMed
    1. Jamal SA, Swan VJ, Brown JP, Hanley DA, Prior JC, Papaioannou A. Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis. 2010;55:291–9. - PubMed
    1. Malluche HH, Monier-Faugere MC. Renal osteodystrophy: what’s in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006;65:235–42. - PubMed

LinkOut - more resources